CXCR4 gene
X4 Pharmaceuticals Restructures to Advance Mavorixafor for Chronic Neutropenia and Optimize XOLREMDI Promotion
X4 Pharmaceuticals, mavorixafor, XOLREMDI, CXCR4 antagonist, WHIM syndrome, chronic neutropenia, workforce reduction, strategic restructuring
X4 Pharmaceuticals’ Xolremdi Granted Approval for Treating Rare Immunodeficiency Disorder
X4 Pharmaceuticals, Xolremdi, approval, rare immunodeficiency disorder, WHIM syndrome, FDA, treatment, breakthrough therapy, CXCR4 antagonist.